Literature DB >> 9720977

Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease.

F J Jiménez-Jiménez1, J A Molina, M V Aguilar, I Meseguer, C J Mateos-Vega, M J González-Muñoz, F de Bustos, A Martínez-Salio, M Ortí-Pareja, M Zurdo, M C Martínez-Para.   

Abstract

We compared CSF and serum levels of iron, copper, manganese, and zinc, measured by atomic absorption spectrophotometry, in 37 patients with Parkinson's disease (PD) and 37 matched controls. The CSF levels of zinc were significantly decreased in PD patients as compared with controls (p < 0.05). The serum levels of zinc, and the CSF and serum levels of iron, copper, and manganese, did not differ significantly between PD-patient and control groups. There was no influence of antiparkinsonian therapy on CSF levels of none of these transition metals. These values were not correlated with age, age at onset, duration of the disease, scores of the Unified Parkinson Disease Rating Scale of the Hoehn and Yahr staging in the PD group, with the exception of CSF copper levels with the duration of the disease (r = 0.38, p < 0.05). These results suggest that low CSF zinc concentrations might be related with the risk for PD, although they could be related with oxidative stress processes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9720977     DOI: 10.1007/s007020050073

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  24 in total

Review 1.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

2.  Mechanism of copper transport at the blood-cerebrospinal fluid barrier: influence of iron deficiency in an in vitro model.

Authors:  Andrew D Monnot; Gang Zheng; Wei Zheng
Journal:  Exp Biol Med (Maywood)       Date:  2012-03

3.  Role of Iron and Copper in the Pathogenesis of Parkinson's Disease.

Authors:  Mohit Kumar Gangania; Jyoti Batra; Suman Kushwaha; Rachna Agarwal
Journal:  Indian J Clin Biochem       Date:  2016-09-03

4.  Relative contribution of CTR1 and DMT1 in copper transport by the blood-CSF barrier: implication in manganese-induced neurotoxicity.

Authors:  Gang Zheng; Jingyuan Chen; Wei Zheng
Journal:  Toxicol Appl Pharmacol       Date:  2012-03-18       Impact factor: 4.219

5.  Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease.

Authors:  Paola Costa-Mallen; Christopher Gatenby; Sally Friend; Kenneth R Maravilla; Shu-Ching Hu; Kevin C Cain; Pinky Agarwal; Yoshimi Anzai
Journal:  J Neurol Sci       Date:  2017-04-23       Impact factor: 3.181

6.  Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk.

Authors:  Paola Costa-Mallen; Cyrus P Zabetian; Pinky Agarwal; Shu-Ching Hu; Dora Yearout; Ali Samii; James B Leverenz; John W Roberts; Harvey Checkoway
Journal:  Parkinsonism Relat Disord       Date:  2015-07-10       Impact factor: 4.891

7.  Carbonic anhydrase I, II, and VI, blood plasma, erythrocyte and saliva zinc and copper increase after repetitive transcranial magnetic stimulation.

Authors:  Robert I Henkin; Samuel J Potolicchio; Lucien M Levy; Ramy Moharram; Irina Velicu; Brian M Martin
Journal:  Am J Med Sci       Date:  2010-03       Impact factor: 2.378

8.  Astrocytes protect against copper-catalysed loss of extracellular glutathione.

Authors:  Simon A S Pope; Rosemary Milton; Simon J R Heales
Journal:  Neurochem Res       Date:  2008-03-12       Impact factor: 3.996

Review 9.  Brain Iron Metabolism Dysfunction in Parkinson's Disease.

Authors:  Hong Jiang; Jun Wang; Jack Rogers; Junxia Xie
Journal:  Mol Neurobiol       Date:  2016-04-02       Impact factor: 5.590

Review 10.  Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.

Authors:  Sarah Jesse; Petra Steinacker; Stefan Lehnert; Frank Gillardon; Bastian Hengerer; Markus Otto
Journal:  CNS Neurosci Ther       Date:  2009-03-09       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.